11 August 2023 in Journal of Burn Care & Research
Acute kidney injury (AKI), a common and severe complication following burn injuries, presents a significant challenge due to its broad clinical manifestations and diverse etiologies. AKI, previously known as acute renal failure, can present abruptly following burns or thermal injuries, causing detrimental health outcomes such as progressive kidney dysfunction, increased hospital length of stay, and requirement of renal replacement therapy (RRT). AKI affects the maintenance of homeostasis of fluid and electrolytes, elimination of metabolic wastes and byproducts, and acid–base balance. Aggressive nutritional support is particularly necessitated in burn patients to prevent protein-energy wasting and a negative nitrogen balance. Understanding the pathogenesis of AKI in burns and improving its prevention and early diagnosis are active areas of research in this field. Despite the potential benefits, the optimal timing and threshold for RRT initiation in burn patients with AKI remain unclear, warranting further studies. Ongoing investigations focus on refining RRT techniques, evaluating biomarkers for early detection of AKI, and exploring adjunctive therapies to enhance renal recovery. The aim of this study is to review the etiology, diagnostic tools, and interventions that improve outcomes associated with AKI in burn-related settings.
11 November 2024 in Pediatric Nephrology
Background: Some inborn errors of metabolism (IEMs) resulting in aberrations to blood leucine and ammonia levels are commonly treated with kidney replacement therapy (KRT). Children with IEMs require prompt treatment, as delayed treatment results in increased neurological and developmental morbidity. Objectives: Our systematic review in neonates and pediatrics evaluates survival rates and reductions in ammonia and leucine levels across different KRT modalities (continuous KRT (CKRT), hemodialysis (HD), peritoneal dialysis (PD)). Data sources: A literature search was conducted through PubMed, Web of Science, and Embase databases for articles including survival rate and toxic metabolite clearance data in pediatric patients with IEM undergoing KRT. Study eligibility criteria: Cross-sectional, prospective, and retrospective studies with survival rates reported in patients with IEM with an intervention of CKRT, PD, or HD were included. Studies with patients receiving unclear or multiple KRT modalities were excluded. Study appraisal and synthesis methods: Analysis variables included efficacy outcomes [% reduction in ammonia (RIA) from pre- to post-dialysis and time to 50% RIA] and mortality. The Newcastle Ottawa Risk of Bias quality assessment was used to assess bias. All statistical analyses were performed with MedCalc Statistical Software version 19.2.6. Results: A total of 37 studies (n = 642) were included. The pooled proportion (95% CI) of mortality on CKRT was 24.84% (20.93–29.08), PD was 34.42% (26.24–43.33), and HD 34.14% (24.19–45.23). A lower trend of pooled (95% CI) time to 50% RIA was observed with CKRT [6.5 (5.1–7.8)] vs. PD [14.4 (13.3–15.5)]. A higher mortality was observed with greater plasma ammonia level before CKRT (31.94% for ≥ 1000 µmol/L vs. 15.04% for < 1000 µmol/L). Conclusions and implications of key findings: Despite the limitations in sample size, trends emerged suggesting that CKRT may be associated with lower mortality rates compared to HD or PD, with potential benefits including prevention of rebound hyperammonemia and improved hemodynamic control. While HD showed a trend towards faster achievement of 50% RIA, all modalities demonstrated comparable efficacy in reducing ammonia and leucine levels. Prospero registration: CRD42023418842. Graphical
7 October 2024 in Physiological Reports
Epidemiological studies have established a link between air pollution and an elevated risk of type 2 diabetes mellitus (T2DM). This study aims to measure the impact of T2DM related to fine particulate matter (PM2.5) pollution by examining death rates and disability‐adjusted life years (DALYs) from 1990 to 2019 in the United States of America. Using data from the Global Burden of Disease (GBD) database, we examined death and DALY rates per 100,000 populations in T2DM patients, specifically focusing on ambient particulate matter pollution (APMP) and household air pollution (HAP). We assessed average annual percentage change (AAPC) across various age and gender groups, states, and socio‐demographic index (SDI) categories. Our findings reveal a significant decline in death rates and DALYs in the United States of America over the last 30 years, with more pronounced decreases among females and older adults. Despite national progress, state‐level variations indicate complex interactions between environmental regulations, healthcare access, and socio‐economic factors. Some states, such as Oregon, Idaho, and Alaska, exhibited increased AAPC. Our study emphasizes the need for targeted policies and interventions to reduce PM2.5 exposure and further address regional disparities, ensuring continued improvement in public health outcomes.
8 November 2023 in Research Square
Pediatric chronic kidney disease (CKD) plays a role in burdening the public health system. Some of this burden can be attributed to comorbidities frequently associated with CKD; however, much of the economic burden is attributed to CKD itself. The economic burden of CKD is difficult to estimate due to variability in the reporting of costs in the literature. In addition, few studies have endeavored to estimate the cost of CKD in the pediatric population, as CKD is not commonly diagnosed in children until the symptoms are observed. Therefore, we extracted data from The Pediatric Health Information System Database (PHIS) to evaluate if the length of stay, hospitalization cost, morbidity, and mortality is higher in patients with CKD than in patients without CKD and to determine if these variables increase over the CKD stage. We found that length of stay (LOS) and hospitalization costs are increased relative to a typical hospitalization. The LOS for patients with CKD 4 and CKD 5 were 22% and 50% longer relative to the LOS of a typical hospitalization, and the cost for these hospitalizations was 128% and 163% higher than that of a typical hospitalization. Morbidity and mortality remain constant through the various stages of CKD. Further investigation is imperative to decrease the financial burden on both patients and the US healthcare system.